241 related articles for article (PubMed ID: 27161622)
1. Large-Scale Screening and Identification of Novel Ebola Virus and Marburg Virus Entry Inhibitors.
Anantpadma M; Kouznetsova J; Wang H; Huang R; Kolokoltsov A; Guha R; Lindstrom AR; Shtanko O; Simeonov A; Maloney DJ; Maury W; LaCount DJ; Jadhav A; Davey RA
Antimicrob Agents Chemother; 2016 Aug; 60(8):4471-81. PubMed ID: 27161622
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Ebola and Marburg Virus Entry by G Protein-Coupled Receptor Antagonists.
Cheng H; Lear-Rooney CM; Johansen L; Varhegyi E; Chen ZW; Olinger GG; Rong L
J Virol; 2015 Oct; 89(19):9932-8. PubMed ID: 26202243
[TBL] [Abstract][Full Text] [Related]
3. Identification of a coumarin-based antihistamine-like small molecule as an anti-filoviral entry inhibitor.
Cheng H; Schafer A; Soloveva V; Gharaibeh D; Kenny T; Retterer C; Zamani R; Bavari S; Peet NP; Rong L
Antiviral Res; 2017 Sep; 145():24-32. PubMed ID: 28645623
[TBL] [Abstract][Full Text] [Related]
4. Identification of Ellagic Acid from Plant Rhodiola rosea L. as an Anti-Ebola Virus Entry Inhibitor.
Cui Q; Du R; Anantpadma M; Schafer A; Hou L; Tian J; Davey RA; Cheng H; Rong L
Viruses; 2018 Mar; 10(4):. PubMed ID: 29584652
[TBL] [Abstract][Full Text] [Related]
5. Identification of an antioxidant small-molecule with broad-spectrum antiviral activity.
Panchal RG; Reid SP; Tran JP; Bergeron AA; Wells J; Kota KP; Aman J; Bavari S
Antiviral Res; 2012 Jan; 93(1):23-9. PubMed ID: 22027648
[TBL] [Abstract][Full Text] [Related]
6. Drug targets in infections with Ebola and Marburg viruses.
Gene OG; Julia BE; Vanessa MR; Victoria WJ; Thomas GW; Lisa HE
Infect Disord Drug Targets; 2009 Apr; 9(2):191-200. PubMed ID: 19275706
[TBL] [Abstract][Full Text] [Related]
7. High-throughput, luciferase-based reverse genetics systems for identifying inhibitors of Marburg and Ebola viruses.
Uebelhoer LS; Albariño CG; McMullan LK; Chakrabarti AK; Vincent JP; Nichol ST; Towner JS
Antiviral Res; 2014 Jun; 106():86-94. PubMed ID: 24713118
[TBL] [Abstract][Full Text] [Related]
8. Identification of filovirus entry inhibitors targeting the endosomal receptor NPC1 binding site.
Wang LL; Palermo N; Estrada L; Thompson C; Patten JJ; Anantpadma M; Davey RA; Xiang SH
Antiviral Res; 2021 May; 189():105059. PubMed ID: 33705865
[TBL] [Abstract][Full Text] [Related]
9. Monoterpenoid-based inhibitors of filoviruses targeting the glycoprotein-mediated entry process.
Sokolova AS; Yarovaya OI; Zybkina AV; Mordvinova ED; Shcherbakova NS; Zaykovskaya AV; Baev DS; Tolstikova TG; Shcherbakov DN; Pyankov OV; Maksyutov RA; Salakhutdinov NF
Eur J Med Chem; 2020 Dec; 207():112726. PubMed ID: 32905862
[TBL] [Abstract][Full Text] [Related]
10. Novel Small Molecule Entry Inhibitors of Ebola Virus.
Basu A; Mills DM; Mitchell D; Ndungo E; Williams JD; Herbert AS; Dye JM; Moir DT; Chandran K; Patterson JL; Rong L; Bowlin TL
J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S425-34. PubMed ID: 26206510
[TBL] [Abstract][Full Text] [Related]
11. Antiviral activity of a small-molecule inhibitor of filovirus infection.
Warren TK; Warfield KL; Wells J; Enterlein S; Smith M; Ruthel G; Yunus AS; Kinch MS; Goldblatt M; Aman MJ; Bavari S
Antimicrob Agents Chemother; 2010 May; 54(5):2152-9. PubMed ID: 20211898
[TBL] [Abstract][Full Text] [Related]
12. Development of treatment strategies to combat Ebola and Marburg viruses.
Paragas J; Geisbert TW
Expert Rev Anti Infect Ther; 2006 Feb; 4(1):67-76. PubMed ID: 16441210
[TBL] [Abstract][Full Text] [Related]
13. In vitro evaluation of cyanovirin-N antiviral activity, by use of lentiviral vectors pseudotyped with filovirus envelope glycoproteins.
Barrientos LG; Lasala F; Otero JR; Sanchez A; Delgado R
J Infect Dis; 2004 Apr; 189(8):1440-3. PubMed ID: 15073681
[TBL] [Abstract][Full Text] [Related]
14. A Novel Ebola Virus VP40 Matrix Protein-Based Screening for Identification of Novel Candidate Medical Countermeasures.
Bennett RP; Finch CL; Postnikova EN; Stewart RA; Cai Y; Yu S; Liang J; Dyall J; Salter JD; Smith HC; Kuhn JH
Viruses; 2020 Dec; 13(1):. PubMed ID: 33396288
[TBL] [Abstract][Full Text] [Related]
15. Ebolavirus delta-peptide immunoadhesins inhibit marburgvirus and ebolavirus cell entry.
Radoshitzky SR; Warfield KL; Chi X; Dong L; Kota K; Bradfute SB; Gearhart JD; Retterer C; Kranzusch PJ; Misasi JN; Hogenbirk MA; Wahl-Jensen V; Volchkov VE; Cunningham JM; Jahrling PB; Aman MJ; Bavari S; Farzan M; Kuhn JH
J Virol; 2011 Sep; 85(17):8502-13. PubMed ID: 21697477
[TBL] [Abstract][Full Text] [Related]
16. Retro-2 and its dihydroquinazolinone derivatives inhibit filovirus infection.
Shtanko O; Sakurai Y; Reyes AN; Noël R; Cintrat JC; Gillet D; Barbier J; Davey RA
Antiviral Res; 2018 Jan; 149():154-163. PubMed ID: 29175127
[TBL] [Abstract][Full Text] [Related]
17. Ebola virus. Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment.
Sakurai Y; Kolokoltsov AA; Chen CC; Tidwell MW; Bauta WE; Klugbauer N; Grimm C; Wahl-Schott C; Biel M; Davey RA
Science; 2015 Feb; 347(6225):995-8. PubMed ID: 25722412
[TBL] [Abstract][Full Text] [Related]
18. Identification of a small-molecule entry inhibitor for filoviruses.
Basu A; Li B; Mills DM; Panchal RG; Cardinale SC; Butler MM; Peet NP; Majgier-Baranowska H; Williams JD; Patel I; Moir DT; Bavari S; Ray R; Farzan MR; Rong L; Bowlin TL
J Virol; 2011 Apr; 85(7):3106-19. PubMed ID: 21270170
[TBL] [Abstract][Full Text] [Related]
19. A high throughput screen identifies benzoquinoline compounds as inhibitors of Ebola virus replication.
Luthra P; Liang J; Pietzsch CA; Khadka S; Edwards MR; Wei S; De S; Posner B; Bukreyev A; Ready JM; Basler CF
Antiviral Res; 2018 Feb; 150():193-201. PubMed ID: 29294299
[TBL] [Abstract][Full Text] [Related]
20. Filovirus proteins for antiviral drug discovery: Structure/function bases of the replication cycle.
Martin B; Canard B; Decroly E
Antiviral Res; 2017 May; 141():48-61. PubMed ID: 28192094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
